AustralianSuper Pty Ltd Sells 10,261 Shares of DaVita Inc. $DVA

AustralianSuper Pty Ltd cut its stake in shares of DaVita Inc. (NYSE:DVA) by 8.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,037 shares of the company’s stock after selling 10,261 shares during the period. AustralianSuper Pty Ltd owned 0.17% of DaVita worth $15,684,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in DVA. Hantz Financial Services Inc. lifted its holdings in shares of DaVita by 48.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of DaVita during the second quarter valued at approximately $43,000. Employees Retirement System of Texas purchased a new position in DaVita during the 2nd quarter valued at about $49,000. SJS Investment Consulting Inc. lifted its position in DaVita by 3,091.7% in the 3rd quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock valued at $51,000 after acquiring an additional 371 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in DaVita by 34.9% during the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock valued at $59,000 after buying an additional 117 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Truist Financial set a $158.00 target price on shares of DaVita in a research note on Thursday, February 5th. Barclays raised their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $155.80.

DaVita Stock Down 1.1%

NYSE DVA opened at $152.25 on Wednesday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $159.42. The business has a fifty day moving average of $125.68 and a 200-day moving average of $126.16. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of 15.36, a price-to-earnings-growth ratio of 0.54 and a beta of 0.94.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.